Apple iPad Pro (Tablet computer)
Boost Mobile is offering the new iPad Pro featuring the powerful M5 chip to its new and current customers. The new iPad Pro can be pre-ordered starting Friday, October 17, with availability beginning on Wednesday, October 22. Boost Mobile customers can add the Tablet Plan for just $20/mo. and
Attention deficit hyperactivity disorder
Researchers investigated the relationship between impulsivity, decision-making, and multisensory integration in individuals with Attention-Deficit/Hyperactivity Disorder (ADHD). The study involved 44 participants, 13 of whom had ADHD or Disruptive Behaviour Disorders, who completed a two-alternative forced-choice task involving visual and auditory stimuli. The results showed that participants performed similarly across
Cardiac patients
A recent study published in the Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease has found that guidelines issued by the American Heart Association/American College of Cardiology/Heart Failure Society of America have had a significant impact on Medicare drug coverage policies for two life-saving medications used
Genes
Researchers at Minia University have made significant findings in the realm of obesity and diabetes, focusing on the genetic factors underlying metabolic dysfunction-associated steatotic liver disease (MASLD). The study, published in the Egyptian Liver Journal, investigated the role of cholesteryl ester transfer protein (CETP) gene variants in MASLD susceptibility. The
Diseases
New research published in a recent study has highlighted the complexities of HIV/AIDS, specifically in patients with advanced disease who experience multijoint pathologies, leading to loss of ambulation and independence. A case report published in JBJS Case Connector in 2024 details the story of a 30-year-old man with a
Antiretroviral agents
Experts in the field of HIV/AIDS research gathered at the Keystone Symposia conference in Durban, South Africa, to discuss novel strategies for eradicating the virus. The conference, held between April 7-10 2025, brought together experts to share their findings on the persistence of HIV reservoirs and the development of
Biochemistry
Research from McGill University has demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) produce modest reductions in blood pressure among individuals with type 2 diabetes and obesity. According to the study, these reductions appear to be driven primarily by weight loss, with additional contributions from potential weight-independent mechanisms such as
Gastrointestinal diseases
Researchers at New York University (NYU) School of Medicine have conducted a nationwide cohort study to identify individuals who remain treatment-free after initial surgery for inflammatory bowel disease (IBD). The study, published in the journal Alimentary Pharmacology & Therapeutics, found that 21.5% of patients with Crohn's disease
Cobicistat
A new study from the University of Paris has found that an antiretroviral therapy regimen known as bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is both safe and effective for elderly individuals living with HIV. The research, which was conducted in collaboration with Gilead Sciences, USA, aimed to evaluate the
Adults
Researchers at Giresun University, Turkey, have published a study examining the relationship between self-esteem, social anxiety, and seizure frequency in adults with epilepsy. The study, published in Epilepsy & Behavior, aimed to determine the self-esteem and social anxiety levels of adult individuals with epilepsy and investigate the moderating effect of
Cardiovascular diseases
Research conducted at the Biomedical Research and Training Institute in Harare, Zimbabwe, has shed light on the cardiovascular disease (CVD) burden among young people living with HIV. The study, published in Current Atherosclerosis Reports, synthesizes current evidence on the CVD burden in this population and highlights critical gaps in understanding
Efavirenz
Research conducted in China has identified a new effective HIV/AIDS treatment option, particularly for individuals switching from lopinavir/ritonavir (LPV/r) based regimens due to treatment failure or intolerance. The study, published in Virologica Sinica, highlights the efficacy and safety of switching to the single-tablet regimen of bictegravir/emtricitabine/
